{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:06:48Z","timestamp":1789016808842,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.clml.2012.11.002","type":"journal-article","created":{"date-parts":[[2012,12,29]],"date-time":"2012-12-29T02:16:07Z","timestamp":1356747367000},"page":"99-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial"],"prefix":"10.1016","volume":"13","author":[{"given":"Jason R.","family":"Westin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vince D.","family":"Cataldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saatva","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perpetua","family":"Sanjorjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick B.","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.11.002_bib1","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","article-title":"Osteoporosis due to cancer treatment: pathogenesis and management","volume":"18","author":"Pfeilschifter","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.11.002_bib2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/gut.51.5.654","article-title":"High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease","volume":"51","author":"Klaus","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.clml.2012.11.002_bib3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Van Staa","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clml.2012.11.002_bib4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses","volume":"39","author":"Van Staa","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clml.2012.11.002_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","article-title":"Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events","volume":"96","author":"Saag","year":"1994","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2012.11.002_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2796.1998.00408.x","article-title":"A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update","volume":"244","author":"Eastell","year":"1998","journal-title":"J Intern Med"},{"key":"10.1016\/j.clml.2012.11.002_bib7","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5","article-title":"Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update","volume":"44","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clml.2012.11.002_bib8","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1001\/archinte.163.21.2619","article-title":"Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs","volume":"163","author":"Adler","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2012.11.002_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2310\/7750.2008.07029","article-title":"Side effects of short-term oral corticosteroids","volume":"12","author":"Richards","year":"2008","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clml.2012.11.002_bib10","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","article-title":"Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer","volume":"14","author":"Bines","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.11.002_bib11","first-page":"1521","article-title":"Osteoporosis in men","volume":"67","author":"Campion","year":"2003","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clml.2012.11.002_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bjc.6604892","article-title":"Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy","volume":"100","author":"Kiserud","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2012.11.002_bib13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.pcan.4500599","article-title":"Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss","volume":"5","author":"Preston","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clml.2012.11.002_bib14","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U","article-title":"Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis","volume":"42","author":"Hochberg","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clml.2012.11.002_bib16","series-title":"Clinician's Guide to Prevention and Treatment of Osteoporosis","year":"2010"},{"key":"10.1016\/j.clml.2012.11.002_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/JCD:7:1:1","article-title":"Official positions of the International Society for Clinical Densitometry","volume":"7","author":"Leib","year":"2004","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.clml.2012.11.002_bib18","unstructured":"Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract; 16(suppl 3):1-37."},{"key":"10.1016\/j.clml.2012.11.002_bib19","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-154-5-201103010-00307","article-title":"Screening for osteoporosis: U.S. preventive services task force recommendation statement","volume":"154","year":"2011","journal-title":"Ann Intern Med"},{"issue":"suppl","key":"10.1016\/j.clml.2012.11.002_bib20","doi-asserted-by":"crossref","first-page":"9055","DOI":"10.1200\/jco.2007.25.18_suppl.9055","article-title":"Osteopenia and osteoporosis in untreated non-Hodgkin's lymphoma patients: an important and potentially treatable survivorship issue in lymphoma","volume":"25","author":"Thompson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.11.002_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2165\/00002512-199914040-00001","article-title":"Bisphosphonate treatment of lytic bone metastases","volume":"14","author":"Lipton","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clml.2012.11.002_bib22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(83)90961-0","article-title":"Comparative study of available medical therapy for hypercalcemia of malignancy","volume":"74","author":"Mundy","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2012.11.002_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0140-6736(83)92755-1","article-title":"Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases","volume":"1","author":"Elomaa","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2012.11.002_bib24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.11.002_bib25","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.11.002_bib26","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial","volume":"14","author":"Conte","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.11.002_bib27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF02555748","article-title":"Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat","volume":"38","author":"Schenk","year":"1986","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clml.2012.11.002_bib28","first-page":"29","article-title":"Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group","volume":"2","author":"Boonekamp","year":"1987","journal-title":"Bone Miner"},{"key":"10.1016\/j.clml.2012.11.002_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/BF02555852","article-title":"Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone","volume":"49","author":"Flanagan","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clml.2012.11.002_bib30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1172\/JCI110704","article-title":"Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro","volume":"70","author":"Reitsma","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2012.11.002_bib31","first-page":"27","article-title":"Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix","volume":"1","author":"Boonekamp","year":"1986","journal-title":"Bone Miner"},{"key":"10.1016\/j.clml.2012.11.002_bib32","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1172\/JCI114100","article-title":"Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow","volume":"83","author":"Hughes","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2012.11.002_bib33","first-page":"81","article-title":"Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat","volume":"48","author":"M\u00fcller","year":"1998","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clml.2012.11.002_bib34","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1359\/jbmr.1998.13.11.1775","article-title":"Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys","volume":"13","author":"Binkley","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clml.2012.11.002_bib35","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.amjmed.2003.12.019","article-title":"Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy","volume":"116","author":"Kim","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2012.11.002_bib36","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clml.2012.11.002_bib37","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clml.2012.11.002_bib38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.11.002_bib39","series-title":"Assessment of osteoporosis at the primary health-care level","author":"Kanis","year":"2008"},{"key":"10.1016\/j.clml.2012.11.002_bib40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s002239900135","article-title":"Biochemical markers of bone turnover reflect femoral bone loss in elderly women","volume":"59","author":"Dresner-Pollak","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clml.2012.11.002_bib41","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1210\/jc.2004-1091","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clml.2012.11.002_bib42","doi-asserted-by":"crossref","unstructured":"Anargyrou K, et al. First-line chemotherapy leads to high bone turnover and reduced bone mass in patients with non-Hodgkin's lymphoma (NHL). Presented at the 51st annual American Society of Hematology meeting. New Orleans: December 5-8. Abstract 114:1951.","DOI":"10.1182\/blood.V114.22.1951.1951"},{"key":"10.1016\/j.clml.2012.11.002_bib43","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1080\/10428190701471973","article-title":"Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures","volume":"48","author":"Cabanillas","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2012.11.002_bib44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1359\/jbmr.090706","article-title":"Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III","volume":"25","author":"Looker","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clml.2012.11.002_bib45","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3109\/07357900902849632","article-title":"Vitamin D and non-Hodgkin lymphoma risk in adults: a review","volume":"27","author":"Kelly","year":"2009","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clml.2012.11.002_bib46","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/jnci\/djm204","article-title":"Prospective study of serum vitamin D and cancer mortality in the United States","volume":"99","author":"Freedman","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2012.11.002_bib47","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.11.002_bib48","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2012.11.002_bib49","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1007\/s11999-010-1535-x","article-title":"Femoral insufficiency fractures associated with prolonged bisphosphonate therapy","volume":"468","author":"Isaacs","year":"2010","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.clml.2012.11.002_bib50","series-title":"A national action plan for cancer survivorship: advancing public health strategies","year":"2004"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:33Z","timestamp":1761870273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012002455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S2152265012002455"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.11.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}